3S56

HIV-1 protease triple mutants V32I, I47V, V82I with antiviral drug saquinavir

Summary for 3S56

Entry DOI	10.2210/pdb3s56/pdb
Related	2NMY 2NMZ 3OXC 3S43 3S53 3S54
Related PRD ID	PRD_000454
Descriptor	Protease, (2S)-N-[(2S,3R)-4-[(2S,3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1 -phenyl-butan-2-yl]-2-(quinolin-2-ylcarbonylamino)butanediamide, ACETATE ION, ... (4 entities in total)
Functional Keywords	saquinavir, hiv/aids, drug resistance, aspartic protease, molecular recognition, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological source	Human immunodeficiency virus 1
Total number of polymer chains	2
Total formula weight	22910.13
Authors	Tie, Y.-F.,Wang, Y.-F.,Weber, I.T. (deposition date: 2011-05-20, release date: 2012-03-21, Last modification date: 2024-02-28)
Primary citation	Tie, Y.,Wang, Y.F.,Boross, P.I.,Chiu, T.Y.,Ghosh, A.K.,Tozser, J.,Louis, J.M.,Harrison, R.W.,Weber, I.T. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci., 21:339-350, 2012 Cited by PubMed: 22238126 DOI: 10.1002/pro.2019 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.88 Å)

Structure validation